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Diagnosis and treatment of TB patients with rifampicin  
resistance detected using Xpert® MTB/RIF in Zimbabwe
K. Charambira,1 S. Ade,2,3 A. D. Harries,2,4 R. T. Ncube,1 C. Zishiri,1 C. Sandy,5 H. Mutunzi,5  
K. Takarinda,2,5 P. Owiti,2 P. Mafaune,5 P. Chonzi6
Zimbabwe is one of the world’s 22 high-burden tu-berculosis (TB) countries, with an estimated TB 
incidence of 552 per 100 000 population in 2013.1 Hu-
man immunodeficiency virus (HIV) prevalence is 17%, 
and 69% of TB patients are co-infected with HIV.1,2 For 
decades, the diagnosis of pulmonary TB has relied on 
sputum smear microscopy, although the test lacks sen-
sitivity and does not detect drug-resistant TB.3,4 The 
early diagnosis of multidrug-resistant TB (MDR-TB, de-
fined as TB resistant to at least both rifampicin [RMP] 
and isoniazid [INH]), is essential to institute prompt 
treatment, reduce mortality and prevent the transmis-
sion of infection.5 In this light, the Xpert® MTB/RIF 
assay (Cepheid Inc, Sunnyvale, CA, USA) is revolu-
tionary, requiring minimal laboratory expertise and 
yielding test results within 2 hours.6 Sensitivity and 
specificity for TB diagnosis is high, and the assay also 
detects RMP resistance. Studies in several settings have 
shown the feasibility, accuracy and effectiveness of 
Xpert,7 prompting the World Health Organization 
(WHO) in 2010 to strongly recommend the wide-
spread use of Xpert, with priority for those with sus-
pected MDR-TB and for patients with TB and HIV 
coinfection.8,9 In 2013, the WHO made a conditional 
recommendation that Xpert should be the initial diag-
nostic test for all people requiring investigation for 
TB.10
Zimbabwe has been scaling up the implementa-
tion of Xpert since 2011. By December 2014, 62 sites 
in the country were using this technology. All indi-
viduals identified with RMP-resistant TB by Xpert 
should be placed immediately on treatment for 
MDR-TB, and their specimens should be processed for 
culture and drug susceptibility testing (CDST), in line 
with previous WHO recommendations.9 There are a 
number of challenges with implementation, however. 
First, national data suggest that the performance of 
CDST after Xpert detection of RMP resistance is poor, 
although this has not been formally studied. Second, 
records indicate that not all patients diagnosed with 
MDR-TB are initiated on treatment. Loss to follow-up 
between the initial diagnosis of TB and the start of 
treatment is known as ‘initial loss to follow-up’ (for-
merly termed ‘initial default’), and is well recognised 
to occur when sputum smears are used for diagno-
sis.11–13 More information is needed about what oc-
curs between the diagnosis of MDR-TB and subse-
quent treatment, and improving this linkage is a key 
priority of the WHO End TB control strategy.14 Third, 
several sites in Zimbabwe have been repeating Xpert 
assays on the same patient following an initial 
RMP-resistant Mycobacterium tuberculosis result, which 
may inadvertently add to the numbers of reported 
initial losses to follow-up and unnecessarily increase 
the consumption of expensive Xpert cartridges (ap-
proximately US$10 per cartridge). More information 
about these challenges will help the National Tuber-
culosis Programme (NTP) in Zimbabwe, as well as in 
other countries, to develop better strategic use of 
Xpert.
The aim of this study was to assess the linkage be-
tween diagnostic and treatment services for patients 
investigated and diagnosed with RMP-resistant TB us-
ing Xpert in two provinces in Zimbabwe (Manicaland 
and Harare City) in 2014. Specific objectives were to 
determine 1) the Xpert assays performed and the 
number and proportion showing resistance to RMP 
(including repeat assays), and 2) the number of pa-
tients identified with RMP resistance by Xpert; the 
number and proportion who had CDST performed 
along with the results; the number and proportion of 
patients who never started MDR-TB treatment and the 
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Setting: In Zimbabwe, there are concerns about the 
management of tuberculosis (TB) patients with rifampicin 
(RMP) resistance diagnosed using Xpert® MTB/RIF.
Objective: To assess linkages between diagnosis and 
treatment for these patients in Harare and Manicaland 
provinces in 2014.
Design: A retrospective cohort study.
Results: Of 20 329 Xpert assays conducted, 90% were 
successful, 11% detected Mycobacterium tuberculosis and 
4.5% showed RMP resistance. Of 77 patients with 
RMP-resistant TB diagnosed by Xpert, 70% had samples 
sent to the reference laboratory for culture and drug sus-
ceptibility testing (CDST); 53% of the samples arrived. In 
21% the samples showed M. tuberculosis growth, and in 
17% the DST results were recorded, all of which con-
firmed RMP resistance. Of the 77 patients, 34 (44%) 
never started treatment for multidrug-resistant (MDR) TB, 
with documented reasons being death, loss to follow-up 
and incorrect treatment. Of the 43 patients who started 
MDR-TB treatment, 12 (71%) in Harare and 17 (65%) in 
Manicaland started within 2 weeks of diagnosis.
Conclusion: Xpert has been rolled out successfully in 
two Zimbabwe provinces. However, the process of con-
firming CDST for Xpert-diagnosed RMP-resistant TB 
works poorly, and many patients are either delayed or 
never initiate MDR-TB treatment. These shortfalls must 
be addressed at the programmatic level.
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reasons why; and, among those who did start treat-
ment, the time taken to initiate MDR-TB treatment.
METHODS
Study design
This was a retrospective cross-sectional study of Xpert 
and a cohort study using routinely collected data to 
follow patients through the process of CDST and 
MDR-TB treatment.
General setting and study sites
Country and provinces
Zimbabwe is a landlocked country in southern Africa 
with an estimated population of 15 million and a gross 
domestic product of US$830 per capita in 2013.15 The 
study was conducted in two provinces, Harare City 
and Manicaland, which have populations of approxi-
mately 2 million and 1.8 million, respectively.16 Public 
health services in the two provinces are discharged 
through the City Health Department and the Provin-
cial Health Directorate. Xpert instruments were made 
available in the provinces in 2012 and 2013, and by 
December 2014, nine Xpert instruments were available 
in each of the two provinces.
The National Tuberculosis Programme and 
management of presumed MDR-TB
The management of MDR-TB in Zimbabwe is coordi-
nated through a designated national MDR-TB focal 
person, and there is a committee in each province and 
district to oversee the clinical and programmatic man-
agement of MDR-TB. The committees have the man-
date of initiating patients on MDR-TB treatment as 
soon as possible.
Patients are deemed to have suspected MDR-TB if 
they are symptomatic and 1) have failed to sputum 
smear convert at 2 months during first-line anti-tuber-
culosis treatment, 2) have a history of previous anti-tu-
berculosis treatment, 3) are contacts of a known index 
patient with MDR-TB, 4) have travelled from a high 
MDR-TB burden country, or 5) have come from high-
risk congregate settings such as prisons. It is recom-
mended that these patients and those with HIV-associ-
ated presumptive TB have Xpert performed on one 
sputum specimen.
The Xpert assay results are recorded in the registers 
of the nine laboratories in Harare City and the nine 
laboratories throughout the province of Manicaland. If 
the Xpert assay shows M. tuberculosis and RMP resis-
tance, further sputum specimens should be submitted 
for CDST at the Harare-based National Microbiology 
Reference Laboratory (NMRL). Once diagnosed with 
RMP-resistant TB by Xpert, all patients should start 
MDR-TB treatment immediately using standardised 
recommended regimens.17 These regimens consist of 
five drugs (kanamycin [KM], levofloxacin [LVX], cy-
closerine [CS], ethionamide [ETH] and pyrazinamide 
[PZA]) for the initial phase of 6–8 months, followed by 
four drugs (LVX, CS, ETH and PZA) for the continua-
tion phase of 14 months. The initial phase is adminis-
tered either in hospital or at home and is directly ob-
served, while the continuation phase is administered 
from home. Prior to treatment, the district MDR-TB 
committee discusses the model of care to be used in 
the management of the patient, whether as an out-pa-
tient or an in-patient for the initial phase. The latter 
model is only used for very ill patients or when infec-
tion control is not achievable at home. Baseline bio-
chemical tests are then conducted before treatment is 
initiated.
Study population
All patients who were tested using Xpert and registered 
in the laboratory registers in the Harare City and Man-
icaland provinces between January and December 
2014 were included in the study.
Data variables, sources of data, data collection 
tools and data validation
Data variables were collected from the Xpert labora-
tory registers and archive files, the CDST register in the 
Harare NMRL and the MDR-TB treatment registers. To 
follow the process of CDST, the names of those found 
to have M. tuberculosis or RMP resistance detected in 
the Xpert registers were searched for in the NMRL reg-
ister in Harare for up to 6 months after the last patient 
was registered in the Xpert laboratory registers.
For data validation, Xpert results in the laboratory 
registers were cross-checked with data extracted from 
the Xpert machines, and data in the treatment regis-
ters were cross-checked with facility-based patient 
medical files. Study data were collected into pa-
per-based questionnaires between March and Novem-
ber 2015.
Analysis and statistics
Data from the paper-based questionnaires were double 
entered and analysed using EpiData software (version 
3.1 for entry and version 2.2.2.182 for analysis, Epi-
Data Association, Odense, Denmark). Data were anal-
ysed by frequencies and percentages, with compari-
sons between the two provinces and between patient 
categories assessed using the χ² test, risk ratios and 
95% confidence intervals (CI). Levels of significance 
were set at 5%.
Ethics
Permission for the study was obtained from the NTP 
and the Medical Research Council, Harare, Zimbabwe. 
The study met the Médecins Sans Frontières (MSF) Eth-
ics Review Board (Geneva, Switzerland) approved crite-
ria for studies of routinely collected data and was ap-
proved by the Ethics Advisory Group of the 
International Union Against Tuberculosis and Lung 
Disease, Paris, France. As this was a record review study 
with anonymised data, informed patient consent was 
not required.
RESULTS
Xpert assays
The number of Xpert assays performed and their re-
sults in both Harare and Manicaland provinces in 
2014 are shown in Figure 1. Of 20 329 assays per-
formed in both provinces, 90% were successful, and 
of these, 11% detected M. tuberculosis. There were 97 
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assays (4.5% of those detecting M. tuberculosis) that showed 
RMP resistance. A comparison between Harare and Manicaland 
of the number of assays performed and their results is shown in 
Table 1. There were some programmatic differences between the 
two sites: the proportion of assays detecting M. tuberculosis was 
higher in Harare, but the proportion of M. tuberculosis assays 
that showed RMP resistance was higher in Manicaland. Alto-
gether, of 77 patients who had RMP resistance on Xpert, 60 had 
one Xpert assay, 14 had two assays and 3 had three assays. 
Thus, 17 (22%) patients with RMP resistance had two or more 
assays done.
Patients with rifampicin resistance on Xpert and CDST 
results
Of the 77 patients who were RMP-resistant on Xpert, the out-
comes of sending samples to the NMRL for CDST for both prov-
inces combined are shown in Figure 2. There were losses at al-
most all stages. Of the 77 patients, 70% had samples sent to the 
reference laboratory for CDST; 53% of the samples arrived and 
were registered at the reference laboratory; 21% of these showed 
growth of M. tuberculosis; and 17% (n = 13) had a DST result re-
corded. All 13 patients were RMP-resistant, and 11 were also 
INH-resistant. The outcomes of sending samples for CDST in Ha-
rare compared with Manicaland are shown in Table 2. There were 
no significant differences at any stage between the two 
provinces.
MDR-TB treatment initiation in rifampicin-resistant 
patients on Xpert
Of the 77 patients detected with RMP-resistant M. tuberculosis, 34 
(44%) were never initiated on MDR-TB treatment. Reasons for 
never starting MDR-TB treatment are shown in Table 3. In two 
thirds of the patients there was no documented reason. Starting a 
first-line anti-tuberculosis treatment regimen, loss to follow-up 
and death were the three documented reasons for not starting ap-
propriate treatment. Sex, HIV status, category of TB and the prov-
ince where the diagnosis was made were not associated with 
never starting MDR-TB treatment (see Table 4).
For the 43 patients who initiated MDR-TB treatment, the time 
from diagnosis to treatment initiation in both provinces is shown 
in Table 5. Most patients (71% in Harare and 65% in Manicaland) 
were initiated on treatment within 2 weeks of diagnosis. There 
were no significant differences in the time from diagnosis to treat-
ment initiation in the provinces.
TABLE 1 Number of Xpert® MTB/RIF assays performed and the results in Harare and 
Manicaland provinces, Zimbabwe, 2014
Xpert assays and results
Harare
n (%)
Manicaland
n (%) P value
Xpert assays performed 13 384 6 945
Successful Xpert assays 12 149 (91) 6 244 (90) 0.02
Xpert assays with M. tuberculosis detected 1 129 (9) 956 (15) 0.001
Xpert assays with M. tuberculosis detected that showed:
 RMP-susceptible bacilli 1 012 (90) 816 (85) 0.001
 RMP-resistant bacilli 36 (3) 61 (6) 0.001
 RMP-indeterminate bacilli 81 (7) 79 (8) 0.41
Unsuccessful Xpert assays 1 235 (9) 701 (10) 0.02
 Error results* 857 (69) 423 (60) 0.001
 No results† 276 (22) 195 (28) 0.003
 Invalid results‡ 101 (8) 84 (12) 0.004
* Error results: probe check control failed and the assay was aborted due to the following: 1) the reaction tube be-
ing filled improperly; 2) a reagent probe integrity problem detected; 3) the maximum pressure limits were ex-
ceeded; 4) an Xpert module failure.
† No results: insufficient data were collected due to 1) power failure; 2) test stopped by the operator.
‡ Invalid results: presence or absence of M. tuberculosis could not be determined due to the following: 1) sample 
processing control did not meet acceptance criteria; 2) sample was not properly processed; 3) PCR was inhibited.
RMP = rifampicin; PCR = polymerase chain reaction.
FIGURE 1 Xpert® MTB/RIF assays performed and results in both Ha-
rare and Manicaland provinces, Zimbabwe, 2014. * Unsuccessful test 
= error result, invalid or no result. †Denominator = total Xpert assays 
performed. ‡Denominator = successful Xpert assays. §Denominator = 
Xpert assays with M. tuberculosis detected. RMP = rifampicin.
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DISCUSSION
This is the first study in Zimbabwe to assess linkages between di-
agnosis and treatment for patients detected with RMP-resistant 
TB using Xpert. There were some important findings. First, large 
numbers of Xpert assays were successfully performed in the two 
provinces in the 12-month period studied. Nearly 5% of M. tuber-
culosis strains showed resistance to RMP, and repeat tests were per-
formed in about one fifth of these patients, although we have no 
information about why the tests were repeated.
Second, the process of sending specimens and obtaining CDST 
results was poor, with only one fifth of the patients detected with 
RMP-resistant strains on Xpert being confirmed by CDST. On a 
positive note, when CDST was performed successfully, all those 
with RMP resistance on Xpert were also confirmed as having RMP 
resistance in the reference laboratory.
Third, almost half of the patients detected with RMP resistance 
on Xpert never started MDR-TB treatment, and the reasons were 
often not documented. Finally, about one third of those who did 
begin MDR-TB treatment had a treatment delay of 2 weeks from 
the date of diagnosis.
The strengths of this study were that it included all Xpert as-
says performed in the two provinces during a 12-month period, 
and included all patients detected with RMP-resistant TB. There 
was therefore no need for any sampling framework. The study 
was conducted under routine programmatic conditions, and ad-
hered to the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) guidelines for conducting and re-
porting on observational studies.18 Limitations included the 
retrospective nature of the study using already collected second-
ary data in registers and archived Xpert files, where some data are 
missing and some may be inaccurately recorded.
There are some important lessons to be learnt. The high suc-
cess rate of the Xpert assays in our programmatic setting study 
compares favourably with recent results reported from a national 
programme study in nearby Swaziland, although the proportion 
FIGURE 2 Patients with RMP resistance on Xpert® MTB/RIF and pro-
cess and performance of CDST in both Harare and Manicaland prov-
inces, Zimbabwe, 2014. * Denominator = patients diagnosed RMP-resis-
tant on Xpert. RMP = rifampicin; CDST = culture and drug susceptibility 
testing; NMRL = National Microbiology Reference Laboratory; MDR-TB 
= multidrug-resistant tuberculosis; DST = drug susceptibility testing.
TABLE 2 Patients resistant to RMP on Xpert® MTB/RIF and the process and performance of CDST at 
the Harare-based NMRL, Harare and Manicaland provinces, Zimbabwe, 2014
Characteristics
Harare
n (%)
Manicaland
n (%) P value
Patients with RMP-resistant TB strains 35 42
Patients with CDST sample sent to the NMRL 22 (63) 32 (76) 0.20
Patients with CDST sample received and registered at the NMRL 19 (54) 22 (52) 0.86
Patients with CDST results in the NMRL register 19 (54) 22 (52) 0.86
Culture results
 No growth 10 (29) 9 (21) 0.47
 M. tuberculosis growth* 5 (14) 11 (26) 0.20
 Contamination 4 (11) 2 (5) 0.51
CDST results received by the referring facility 16 (46) 17 (40) 0.64
* DST showed: RMP monoresistance (n = 2); MDR (n = 10); polydrug resistance, including RMP (n = 1); missing DST results 
(n = 3).
RMP = rifampicin; CDST = culture and drug susceptibility testing; NMRL = National Microbiology Reference Laboratory; TB = 
tuberculosis; MDR = multidrug resistance; DST = drug susceptibility testing.
TABLE 3 Reasons for never starting MDR-TB treatment in patients 
with RMP resistance on Xpert® MTB/RIF in both Harare and 
Manicaland provinces, Zimbabwe, 2014
Reason for never starting MDR-TB treatment n (%)
Started treatment with first line anti-tuberculosis drugs 5 (15)
Lost to follow-up 3 (9)
Death 4 (12)
Not documented 22 (64)
 Total 34 
MDR-TB = multidrug-resistant tuberculosis; RMP = rifampicin; TB = tuberculosis.
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of unsuccessful assays in Zimbabwe was higher than in 
Swaziland.19
The system of sending sputum specimens and receiving the re-
sults back between the peripheral health facilities and the central 
reference laboratory in Harare did not work. At each stage there 
were losses, and when the specimens finally did arrive at the labo-
ratory, over half failed to successfully grow M. tuberculosis. This 
problem of sending samples to a central reference laboratory is 
not unique to Zimbabwe; similar challenges are encountered in 
many other countries.20–24 Trying to fix these challenges is also 
not easy, as described in a case study from Malawi.20 As several 
studies, including our own, have highlighted the high sensitivity 
and specificity of Xpert compared with phenotypic CDST under 
routine programme settings,7,9,25 we question the need for CDST 
to confirm RMP-resistant TB. CDST might be better used 1) to di-
agnose resistance to second-line anti-tuberculosis results and thus 
help to diagnose extensively drug resistant (XDR) TB (MDR-TB 
that is also resistant to both any fluoroquinolone and one of the 
injectable second-line drugs) or pre-XDR-TB (MDR-TB resistant to 
either any fluoroquinolone or one of the injectable second-line 
drugs); and 2) to follow up patients who are failing MDR-TB 
treatment.
It is unacceptable for any patient diagnosed with MDR-TB 
never to start treatment or to start treatment after several weeks 
of delay. Again, this problem is not unique to Zimbabwe. Of the 
300 000 notified TB patients estimated to have MDR-TB globally 
in 2014, only 110 000 (37%) started MDR-TB treatment, and of 
these, only 50% successfully completed treatment.26 Possible rea-
sons for delays in starting treatment in Zimbabwe might be the 
time taken in conducting the baseline biochemistry tests on liver 
and renal function and the decision to start MDR-TB treatment, 
which is made by the clinical management team. Previous studies 
conducted elsewhere have shown that delayed treatment is due to 
a combination of patient and health system factors,27–29 and these 
need to be addressed.
This study has several implications for the NTP. First, Xpert in-
struments need to be functional at all times, with unsuccessful 
tests reduced to a minimum. This means attention by the NTP to 
maintenance, calibration, uninterrupted power supplies and con-
sistent external back-up of data. Second, we suggest that the cur-
rent recommendations of using CDST for confirming Xpert RMP 
resistance be revised. Third, all patients who are diagnosed with 
MDR-TB must start MDR-TB treatment. The process of initiating a 
patient on MDR-TB treatment after diagnosis is quite complicated 
in Zimbabwe, requiring biochemical tests that may not always be 
available at the clinical level and a decision by a specific commit-
tee; all of these steps may delay the start of treatment. This pro-
cess needs to be reviewed to see whether it can be simplified. Also, 
instead of evaluating treatment outcomes on those registered for 
treatment, it would be better and more honest, as suggested pre-
viously,12,13 to evaluate outcomes in those diagnosed with 
MDR-TB and recording as a treatment outcome ‘initial loss to fol-
low-up’. Finally, we need qualitative research to better understand 
why some patients do not start MDR-TB treatment.
In conclusion, although the roll-out of Xpert technology in 
two provinces in Zimbabwe has been successful, there were short-
comings with respect to the central reference laboratory confir-
mation of RMP-resistant TB diagnosis and the timely linkage of 
patients to MDR-TB treatment. These shortcomings must be ad-
dressed. With the international community signed up to end the 
TB epidemic by 2030,30 attention to these programme issues will 
be essential if this goal is to be realised.
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Contexte  :  Au Zimbabwe, la prise en charge des patients tuberculeux 
ayant une résistance à la rifampicine (RMP) diagnostiqués par Xpert® 
MTB/RIF est préoccupante.
Objectif  :  Evaluer les liens entre le diagnostic et le traitement de ces 
patients dans les provinces de Harare et de Manicaland en 2014.
Schéma  :  Etude rétrospective de cohorte.
Résultats  :  Sur 20 329 tests Xpert, 90% ont été réussis, 11% ont 
détecté Mycobacterium tuberculosis et 4,5% ont mis en évidence 
une résistance à la RMP. Il y a eu 77 patients atteints d’une 
tuberculose (TB) résistante à la RMP diagnostiqués par Xpert. Parmi 
eux, 70% ont bénéficié d’un envoi d’échantillon au laboratoire de 
référence pour une culture et un test de pharmacosensibilité 
(CDST) ; pour 53% d’entre eux, les échantillons sont arrivés à bon 
port ; pour 21%, les échantillons ont mis en évidence une 
croissance de M. tuberculosis ; et chez 17%, les résultats du CDST 
ont été enregistrés et tous ont confirmé la résistance à la RMP. Sur 
77 patients, 34 (44%) n’ont jamais mis en route un traitement 
pour le TB multirésistante (TB-MDR) ; les motifs documentés 
étaient le décès, la perte de vue ou un traitement incorrect. Des 43 
patients qui ont débuté le traitement de TB-MDR, 12 (71%) à 
Harare et 17 (65%) au Manicaland ont commencé dans les 2 
semaines suivant le diagnostic.
Conclusion  :  L’Xpert a été lancé avec succès dans deux provinces du 
Zimbabwe. Cependant, le processus de confirmation du CDST pour 
une TB résistante à la RMP diagnostiquée par Xpert ne fonctionne pas 
bien, et de nombreux patients sont soit traités avec retard, soit ne 
démarrent jamais le traitement de TB-MDR. Ces problèmes doivent 
être examinés par le programme.
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Marco de referencia: En Zimbabwe, el tratamiento de los pacientes 
cuyo diagnóstico de tuberculosis (TB) resistante a la rifampicina 
(RMP) se determina mediante la prueba Xpert® MTB/RIF es fuente de 
inquietud.
Objetivo: Evaluar los nexos entre el diagnóstico y el tratamiento de 
los pacientes diagnosticados mediante la prueba Xpert en las 
provincias de Harare y Manicaland en el 2014.
Método: Fue este un estudio retrospectivo de cohortes.
Resultados: Se obtuvieron resultados satisfactorios en el 90% de las 
20 329 pruebas Xpert realizadas; se detectó Mycobacterium 
tuberculosis en el 11% y el 4,5% reveló resistencia a RMP. Con la 
prueba Xpert se diagnosticaron 77 casos de TB resistente a RMP y se 
enviaron muestras del 70% de estos casos al laboratorio de referencia, 
con el fin de practicar el cultivo y las pruebas se sensibilidad (CDST) a 
los medicamentos antituberculosos. El 53% de estas muestras 
llegaron al laboratorio, en un 21% se obtuvo crecimiento de M. 
tuberculosis y en el 17% de los casos existía un registro de los 
resultados de la CDST; todos los resultados confirmaron la resistencia 
a RMP. De los 77 pacientes, 34 nunca comenzaron el tratamiento 
contra la TB multidrogorresistente (TB-MDR) (44%); las causas 
documentadas fueron el fallecimiento, la pérdida durante el 
seguimiento y un tratamiento inadecuado. De los 43 pacientes que 
iniciaron el tratamiento por TB-MDR, 12 casos en Harare (71%) y 17 
casos en Manicaland (65%) lo comenzaron en las 2 primeras semanas 
después del diagnóstico.
Conclusión: El despliegue de la prueba Xpert en dos provincias de 
Zimbabwe fue satisfactorio. Sin embargo, el mecanismo de 
confirmación de la resistencia a RMP mediante el CDST en los casos 
diagnosticados por la prueba Xpert fue deficiente y en muchos 
pacientes se retrasó el tratamiento de la TB-MDR o nunca se 
comenzó. Es preciso abordar estas deficiencias en el marco 
programático.
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